Company Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1989 |
| IPO Date | Feb 4, 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 314 |
| CEO | Dominick Colangelo |
Contact Details
Address: 64 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 588 5555 |
| Website | vcel.com |
Stock Details
| Ticker Symbol | VCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000887359 |
| CUSIP Number | 92346J108 |
| ISIN Number | US92346J1088 |
| Employer ID | 94-3096597 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dominick C. Colangelo Esq. | Chief Executive Officer, President and Director |
| Joseph Anthony Mara Jr. | Chief Financial Officer and Treasurer |
| Michael Halpin | Chief Operating Officer |
| Sean C. Flynn | Chief Legal Officer |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
| Jonathan D. Siegal | Principal Accounting Officer, Vice President and Corporate Controller |
| Eric Burns | Vice President of Finance and Investor Relations |
| Patrick J. Fowler | Senior Vice President of Corporate Development and Strategy |
| Patrick Helfrich | Vice President of Marketing and Commercial Strategy |
| Mike Gilligan | Senior Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |